Skip to main content


Fig. 4 | Cancer Communications

Fig. 4

From: CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Fig. 4

Kaplan–Meier analysis for the duration of treatment response. Median DOR was significantly longer in patients who received CMAB009 plus irinotecan compared with those who received irinotecan-only. DOR, duration of response

Back to article page